159 related articles for article (PubMed ID: 34079223)
1. Enhanced Accumulation of Cisplatin in Ovarian Cancer Cells from Combination with Wedelolactone and Resulting Inhibition of Multiple Epigenetic Drivers.
Sarwar S; Alamro AA; Alghamdi AA; Naeem K; Ullah S; Arif M; Yu JQ; Huq F
Drug Des Devel Ther; 2021; 15():2211-2227. PubMed ID: 34079223
[TBL] [Abstract][Full Text] [Related]
2. Synthesis of a monofunctional platinum compound and its activity alone and in combination with phytochemicals in ovarian tumor models.
Arzuman L; Beale P; Yu JQ; Proschogo N; Huq F
Anticancer Res; 2014 Dec; 34(12):7077-90. PubMed ID: 25503135
[TBL] [Abstract][Full Text] [Related]
3. Synthesis of trans-bis-(2-hydroxypyridine)dichloroplatinum(II) and its activity in human ovarian tumour models.
Deqnah N; Yu JQ; Beale P; Fisher K; Huq F
Anticancer Res; 2012 Jan; 32(1):135-40. PubMed ID: 22213298
[TBL] [Abstract][Full Text] [Related]
4. Studies on combinations of platinum with paclitaxel and colchicine in ovarian cancer cell lines.
Yunos NM; Beale P; Yu JQ; Strain D; Huq F
Anticancer Res; 2010 Oct; 30(10):4025-37. PubMed ID: 21036717
[TBL] [Abstract][Full Text] [Related]
5. Epigallocatechin gallate acts synergistically in combination with cisplatin and designed trans-palladiums in ovarian cancer cells.
Mazumder ME; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2012 Nov; 32(11):4851-60. PubMed ID: 23155251
[TBL] [Abstract][Full Text] [Related]
6. Monofunctional Platinum-containing Pyridine-based Ligand Acts Synergistically in Combination with the Phytochemicals Curcumin and Quercetin in Human Ovarian Tumour Models.
Arzuman L; Beale P; Yu JQ; Huq F
Anticancer Res; 2015 May; 35(5):2783-94. PubMed ID: 25964558
[TBL] [Abstract][Full Text] [Related]
7. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
8. Combination of Genistein and Cisplatin with Two Designed Monofunctional Platinum Agents in Human Ovarian Tumour Models.
Arzuman L; Beale P; Proschogo N; Yu JQ; Huq F
Anticancer Res; 2015 Nov; 35(11):6027-39. PubMed ID: 26504026
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and antitumour activity of a new trinuclear platinum compound [{cis-PtCl(NH3)2μ {trans-Pt(3-hydroxypyridine)2H2N(CH2)5NH2)2}] Cl4 in human ovarian cancer cells.
Hamad SA; Beale P; Yu JQ; Huq F
Anticancer Res; 2014 Apr; 34(4):1923-9. PubMed ID: 24692727
[TBL] [Abstract][Full Text] [Related]
10. Studies on synthesis, activity and binding with DNA of a new trinuclear platinum compound [{trans-PtCl(NH3)2}2{trans-Pt(thiazole)2}{H2N(CH2)(6NH2}2]Cl3(NO3).
Al-Shuneigat J; Qing Y; Beale P; Fisher K; Huq F
Med Chem; 2011 Jan; 7(1):1-8. PubMed ID: 21235513
[TBL] [Abstract][Full Text] [Related]
11. Synergistic Cytotoxic Effect from Combination of Wedelolactone and Cisplatin in HeLa Cell Line: A Novel Finding.
Sarwar S; Yu JQ; Nadeem H; Huq F
Drug Des Devel Ther; 2020; 14():3841-3852. PubMed ID: 33061291
[TBL] [Abstract][Full Text] [Related]
12. Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.
Liu YK; Jia YJ; Liu SH; Shi HJ; Ma J
Histol Histopathol; 2021 May; 36(5):535-545. PubMed ID: 33570156
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and activity of a trinuclear platinum complex: [{trans-PtCl(NH3)2}2mu-{trans-Pt(3-hydroxypyridine)2(H2N(CH2)6NH2)2}]Cl4 in ovarian cancer cell lines.
Tayyem H; Huq F; Yu JQ; Beale P; Fisher K
ChemMedChem; 2008 Jan; 3(1):145-51. PubMed ID: 17963210
[TBL] [Abstract][Full Text] [Related]
14. Changes in the in vitro activity of platinum drugs when administered in two aliquots.
Al-Eisawi Z; Beale P; Chan C; Yu JQ; Proschogo N; Molloy M; Huq F
BMC Cancer; 2016 Aug; 16(1):688. PubMed ID: 27566066
[TBL] [Abstract][Full Text] [Related]
15. Synergism from sequenced combinations of curcumin and epigallocatechin-3-gallate with cisplatin in the killing of human ovarian cancer cells.
Yunos NM; Beale P; Yu JQ; Huq F
Anticancer Res; 2011 Apr; 31(4):1131-40. PubMed ID: 21508356
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of the IGF signaling pathway reverses cisplatin resistance in ovarian cancer cells.
Du J; Shi HR; Ren F; Wang JL; Wu QH; Li X; Zhang RT
BMC Cancer; 2017 Dec; 17(1):851. PubMed ID: 29241458
[TBL] [Abstract][Full Text] [Related]
17. Anti-proliferative and pro-apoptotic effects from sequenced combinations of andrographolide and cisplatin on ovarian cancer cell lines.
Yunos NM; Mutalip SS; Jauri MH; Yu JQ; Huq F
Anticancer Res; 2013 Oct; 33(10):4365-71. PubMed ID: 24123004
[TBL] [Abstract][Full Text] [Related]
18. Combinations of resveratrol, cisplatin and oxaliplatin applied to human ovarian cancer cells.
Nessa MU; Beale P; Chan C; Yu JQ; Huq F
Anticancer Res; 2012 Jan; 32(1):53-9. PubMed ID: 22213288
[TBL] [Abstract][Full Text] [Related]
19. Sequenced Combinations of Cisplatin and Selected Phytochemicals towards Overcoming Drug Resistance in Ovarian Tumour Models.
Althurwi SI; Yu JQ; Beale P; Huq F
Int J Mol Sci; 2020 Oct; 21(20):. PubMed ID: 33053689
[TBL] [Abstract][Full Text] [Related]
20. Studies on two new mixed ligand platinum compounds with a trans-geometry.
Al-Shuneigat J; Yu JQ; Beale P; Fisher K; Huq F
Med Chem; 2010 Sep; 6(5):321-8. PubMed ID: 20977416
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]